These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1974513)

  • 1. Effects of carvedilol on renal function.
    Dupont AG
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S96-100. PubMed ID: 1974513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension.
    Dupont AG; Van der Niepen P; Taeymans Y; Ingels M; Piepsz A; Bossuyt AM; Block P; Six RO; Jonckheer MH; Vanhaelst L
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S130-6. PubMed ID: 2454359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of long-term carvedilol therapy on renal function in essential hypertension.
    Tomita K; Marumo F
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S97-101. PubMed ID: 1378158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carvedilol and the kidney.
    Dupont AG
    Clin Investig; 1992; 70 Suppl 1():S127-31. PubMed ID: 1350479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.
    Heitmann M; Davidsen U; Stokholm KH; Rasmussen K; Burchardt H; Petersen EB
    Scand J Clin Lab Invest; 2002; 62(2):97-104. PubMed ID: 12004934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension.
    Ruilope LM
    Am J Hypertens; 1994 Feb; 7(2):129-36. PubMed ID: 7910028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian antihypertensive profile of carvedilol (BM 14190).
    Meyer-Sabellek W; Schulte KL; Distler A; Gotzen R
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S119-23. PubMed ID: 2454357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide.
    Widmann L; van der Does R; Hörrmann M; Machwirth M
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S143-6. PubMed ID: 1974505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension.
    Ollivier JP; Durier P; Bussiere JL; Gayet JL
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S164-6. PubMed ID: 1974509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-pressure-lowering effect of carvedilol vs nitrendipine in geriatric hypertensives.
    Krönig B; Widmann L; Staiger C; Machwirth M; Stienen U; Hennig M; Müller-Beckmann B
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S167-70. PubMed ID: 1974510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance.
    Morgan T; Snowden R; Butcher L
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S124-9. PubMed ID: 2454358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of early carvedilol treatment and withdrawal on the development of hypertension and renal vascular narrowing.
    Kett MM; Denton KM; Boesen EI; Anderson WP
    Am J Hypertens; 2004 Feb; 17(2):161-6. PubMed ID: 14751659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study.
    McPhillips JJ; Schwemer GT; Scott DI; Zinny M; Patterson D
    Drugs; 1988; 36 Suppl 6():82-91. PubMed ID: 2908306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic and renal hemodynamic effects of celiprolol in essential hypertensives.
    Lucarini AR; Salvetti A
    Am J Cardiol; 1988 Feb; 61(5):45C-48C. PubMed ID: 2963525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
    Deetjen A; Heidland A; Pangerl A; Meyer-Sabellek W; Schaefer RM
    Clin Nephrol; 1995 Jan; 43(1):47-52. PubMed ID: 7697935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response rate with respect to the blood pressure-lowering effect of the vasodilating and beta-blocking agent carvedilol.
    Rittinghausen R
    Drugs; 1988; 36 Suppl 6():92-101. PubMed ID: 2908307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.
    Wong GW; Laugerotte A; Wright JM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007449. PubMed ID: 26306578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats.
    Barone FC; Nelson AH; Ohlstein EH; Willette RN; Sealey JE; Laragh JH; Campbell WG; Feuerstein GZ
    J Pharmacol Exp Ther; 1996 Nov; 279(2):948-55. PubMed ID: 8930204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan.
    Kohno M; Takeda T; Ishii M; Saruta T; Mizuno Y; Yoshimura M; Kubo S; Fukiyama K; Fujishima M
    Drugs; 1988; 36 Suppl 6():129-35. PubMed ID: 2908299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of carvedilol in elderly hypertensive patients.
    Morgan TO; Anderson A; Cripps J; Adam W
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S129-33. PubMed ID: 1974503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.